Hemostasis and coagulation analyzers are medical devices used to test blood coagulation and help in detecting blood clotting disorders. These analyzers perform various tests such as prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, and thrombin time tests. They help physicians in monitoring anticoagulant therapy and assist in preventing life-threatening blood loss during surgeries. The growing prevalence of blood clotting disorders such as deep vein thrombosis and pulmonary embolism is driving the demand for hemostasis and coagulation analyzers globally.

The Global Hemostasis/ Coagulation Analyzer Market  is estimated to be valued at US$ 6.47 Bn  in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Hemostasis/ Coagulation Analyzer Market Growth are Horiba Medical, Siemens Healthineers AG, Agappe Diagnostics Ltd, NIHON KOHDEN CORPORATION, Sysmex Corporation, F. Hoffmann-La Roche Ltd, Stago Group, Maccura Biotechnology Co., Ltd., Thermo Fisher Scientific Inc., Haemonetics Corporation, Genrui Biotech Co., Ltd., BIOLABO S.A.S, Erba Mannheim, Sclavo Diagnostics International, and Helena Laboratories Corporation. These players are focusing on new product launches and enabling technologies to gain a competitive edge in the market.

The growing incidence of cardiovascular diseases, trauma injuries, transplantation surgeries, and increasing geriatric population and obesity rates are anticipated to generate more demand for coagulation testing. This presents lucrative opportunities for players in the hemostasis and coagulation analyzer market to expand their offerings and penetrate untapped markets.

Major players are strategizing global expansion plans by strengthening their distribution networks across developed and emerging countries. For instance, Sysmex formed cooperation with Maruho for hemostasis analyzers sales and support in 50 countries across the Middle East, Africa, and Asia. In addition, companies are gaining approvals to market their analyzers in different geographic regions, which will further support global market growth over the forecast period.

Market drivers:

- Growing incidence of blood disorders: The rising global prevalence of blood disorders like deep vein thrombosis and pulmonary embolism due to sedentary lifestyle is a key driver for the market.

- Increasing surgical procedures: Growing number of surgeries lead to use of hemostasis testing for blood clotting, thereby driving market growth.

Market restraints:

- High capital investment: Hemostasis analyzers require huge capital investments and infrastructural setup that may restraint its adoption in low resource settings.

- Stringent regulations: Hemostasis devices are subject to stringent regulations pertaining to safety, efficacy which increases compliance costs for manufacturers.

Segment Analysis

The hemostasis and coagulation analyzer market is dominated by the clinical laboratory segment. Clinical laboratories perform a large number of coagulation tests to manage patients on anticoagulant therapy and to diagnose bleeding and clotting disorders. The availability of automated, high-volume coagulation analyzers suitable for healthcare settings with medium to high testing volumes favors the growth of this segment.

The point-of-care testing segment is another promising sub-segment in the market. Point-of-care coagulation testing allows fast test results bedside or in emergency departments and operating rooms. This helps facilitate timely clinical decision making. The development of user-friendly portable devices for near-patient and point-of-care testing is expected to drive the growth of this segment during the forecast period.

Regional Analysis

North America currently dominates the hemostasis and coagulation analyzer market due to the high patient awareness levels and ready availability of automated systems. The Asia Pacific region is expected to witness the highest growth during the forecast period owing to improving healthcare infrastructure, rising medical tourism, and increasing adoption of automated analyzers in major Asian countries. Within the Asia Pacific, China and India are expected to be the fastest growing markets due to growing geriatric population, rising healthcare expenditures, and increasing focus of global market players in these countries. Europe is also expected to exhibit significant growth due to supportive government initiatives encouraging the adoption of advanced laboratory medical technologies.

Get More Insights On This Topic: Hemostasis/Coagulation Analyzer Market